CytRx (CYTR) – FDA
-
CytRx (CYTR) Highlights Orphazyme's Completion of Rolling Submission of its NDA with the U.S. FDA for Arimoclomol in Niemann-Pick Disease Type-C
-
CytRx (CYTR) Reports Orphazyme Granted FDA Fast Track Designation for Development of Arimoclomol in Amyotrophic Lateral Sclerosis
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to CYTR Stock Lookup